Plasma amyloid-β, Aβ1-42, load is reduced by haemodialysis

Journal of Alzheimer's Disease

Volumn 10, Issue 4, 2006, Pages 439-443

  Rubio, Isabel ^a   Caramelo, Carlos ^b   Gil, Ascención ^c   López, María Dolores ^b   De Yébenes, Justo García ^a,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Amyloid; Dementia; Haemodialysis; Plasma; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; COPPER; ZINC;

ADULT; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 33846961426     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-10413     Document Type: Article

References (46)

1. M.J. Alter, M.S. Favero, J.K. Miller, L.A. Moyer and L.A. Bland, National surveillance of dialysis-associated diseases in the United States, 1987, ASAIO Trans 35 (1989), 820-831.
2. N. Andreasen, E. Vanmechelen, H. Vanderstichele, P. Davidsson and K. Blennow, Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment, Acta Neurol Scand Suppl 179 (2003), 47-51.
3. R.A. Bech, G.Waldemar, F. Gjerris, L. Klinken and M. Juhler, Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings, Acta Neurochir (Wien) 141 (1999), 633-639.
4. D.R. Brown and H. Kozlowski, Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases, Dalton Trans (2004), 1907-1917.
5. E. Carro, C. Spuch, J.L. Trejo, D. Antequera and I. Torres-Aleman, Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I, J Neurosci 25 (2005), 10884-10893.
6. E. Carro, J.L. Trejo, A. Gerber, H. Loetscher, J. Torrado, F. Metzger and I. Torres-Aleman, Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis, Neurobiol Aging (2005).
7. E. Carro, J.L. Trejo, T. Gomez-Isla, D. LeRoith and I. Torres-Aleman, Serum insulin-like growth factor I regulates brain amyloid-beta levels, Nat Med 8 (2002), 1390-1397.
8. W. Cerpa, L. Varela-Nallar, A.E. Reyes, A.N. Minniti and N.C. Inestrosa, Is there a role for copper in neurodegenerative diseases? Mol Aspects Med 26 (2005), 405-420.
9. R. Deane, A. Sagare, K. Hamm, M. Parisi, B. LaRue, H. Guo, Z. Wu, D.M. Holtzman and B.V. Zlokovic, IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor, J Neurosci 25 (2005), 11495-11503.
10. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul and D.M. Holtzman, Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, Proc Natl Acad Sci USA 98 (2001), 8850-8855.
11. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul and D.M. Holtzman, Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science 295 (2002), 2264-2267.
12. S. Devanathan, Z. Salamon, G. Lindblom, G. Grobner and G. Tollin, Effects of sphingomyelin, cholesterol and zinc ions on the binding, insertion and aggregation of the amyloid Abeta(1-40) peptide in solid-supported lipid bilayers, Febs J 273 (2006), 1389-1402.
13. R.C. Dodel, H. Hampel and Y. Du, Immunotherapy for Alzheimer's disease, Lancet Neurol 2 (2003), 215-220.
14. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, L. Jenkins and M. Koller, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology 64 (2005), 1563-1572.
15. H. Fukumoto, M. Tennis, J.J. Locascio, B.T. Hyman, J.H. Growdon and M.C. Irizarry, Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels, Arch Neurol 60 (2003), 958-964.
16. I. Fukunishi, T. Kitaoka, T. Shirai, K. Kino, E. Kanematsu and Y. Sato, Psychiatric disorders among patients undergoing hemodialysis therapy, Nephron 91 (2002), 344-347.
17. K. Garai, P. Sengupta, B. Sahoo and S. Maiti, Selective destabilization of soluble amyloid beta oligomers by divalent metal ions, Biochem Biophys Res Commun 345 (2006), 210-215.
18. M.N. Gaugler, J. Tracy, K. Kuhnle, A. Crameri, R.M. Nitsch and M.H. Mohajeri, Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo, FEBS Lett 579 (2005), 753-756.
19. J.F. Ghersi-Egea, P.D. Gorevic, J. Ghiso, B. Frangione, C.S. Patlak, and J.D. Fenstermacher, Fate of cerebrospinal fluidborne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries, J Neurochem 67 (1996), 880-883.
20. J. Ghiso, M. Calero, E. Matsubara, S. Governale, J. Chuba, R. Beavis, T. Wisniewski and B. Frangione, Alzheimer's soluble amyloid beta is a normal component of human urine, FEBS Lett 408 (1997), 105-108.
21. J. Ghiso, M. Shayo, M. Calero, D. Ng, Y. Tomidokoro, S. Gandy, A. Rostagno and B. Frangione, Systemic catabolism of Alzheimer's Abeta40 and Abeta42, J Biol Chem 279 (2004), 45897-45908.
22. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
23. J. Golomb, J. Wisoff, D.C. Miller, I. Boksay, A. Kluger, H. Weiner, J. Salton and W. Graves, Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response, J Neurol Neurosurg Psychiatry 68 (2000), 778-781.
24. K.M. Hayden, P.P. Zandi, C.G. Lyketsos, A.S. Khachaturian, L.A. Bastian, G. Charoonruk, J.T. Tschanz, M.C. Norton, C.F. Pieper, R.G. Munger, J.C. Breitner and K.A. Welsh-Bohmer, Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study, Alzheimer Dis Assoc Disord 20 (2006), 93-100.
25. S.C. Hung, S.H. Hung, D.C. Tarng, W.C. Yang, T.W. Chen and T.P. Huang, Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients, Am J Kidney Dis 38 (2001), 941-947.
26. N.C. Inestrosa, W. Cerpa and L. Varela-Nallar, Copper brain homeostasis: role of amyloid precursor protein and prion protein, IUBMB Life 57 (2005), 645-650.
27. M.C. Irizarry, M.E. Gurol, S. Raju, R. Diaz-Arrastia, J.J. Locascio, M. Tennis, B.T. Hyman, J.H. Growdon, S.M. Greenberg and T. Bottiglieri, Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease, Neurology 65 (2005), 1402-1408.
28. T. Iwatsubo, Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease, Neurobiol Aging 19 (1998), 161-163.
29. M. Kivipelto, T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kareholt, B. Winblad, E.L. Helkala, J. Tuomilehto, H. Soininen and A. Nissinen, Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease, Arch Neurol 62 (2005), 1556-1560.
30. A.O. Koob and R.B. Borgens, Polyethylene glycol treatment after traumatic brain injury reduces beta-amyloid precursor protein accumulation in degenerating axons, J Neurosci Res 83 (2006), 1558-1563.
31. Y.M. Kuo, M.R. Emmerling, C. Vigo-Pelfrey, T.C. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, M.J. Ball and A.E. Roher, Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains, J Biol Chem 271 (1996), 4077-4081.
32. R. Mayeux, L.S. Honig, M.X. Tang, J. Manly, Y. Stern, N. Schupf and P.D. Mehta, Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk, Neurology 61 (2003), 1185-1190.
33. K.V. Nguyen, J.L. Gendrault and C.M. Wolff, Poly-L-lysine dissolves fibrillar aggregation of the Alzheimer beta-amyloid peptide in vitro, Biochem Biophys Res Commun 291 (2002), 764-768.
34. E. Reusche, V. Koch, B. Lindner, A.P. Harrison and H.J. Friedrich, Alzheimer morphology is not increased in dialysis-associated encephalopathy and long-term hemodialysis, Acta Neuropathol (Berl) 101 (2001), 211-216.
35. P. Rzepecki, L. Nagel-Steger, S. Feuerstein, U. Linne, O. Molt, R. Zadmard, K. Aschermann, M. Wehner, T. Schrader and D. Riesner, Prevention of Alzheimer's disease-associated Abeta aggregation by rationally designed nonpeptidic beta-sheet ligands, J Biol Chem 279 (2004), 47497-47505.
36. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400 (1999), 173-177.
37. D. Schenk, M. Hagen and P. Seubert, Current progress in beta-amyloid immunotherapy, Curr Opin Immunol 16 (2004), 599-606.
38. D. Scheuner, C. Eckman, M. Jensen, X. Song, M. Citron, N. Suzuki, T.D. Bird, J. Hardy, M. Hutton, W. Kukull, E. Larson, E. Levy-Lahad, M. Viitanen, E. Peskind, P. Poorkaj, G. Schellenberg, R. Tanzi, W. Wasco, L. Lannfelt, D. Selkoe and S. Younkin, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nat Med 2 (1996), 864-870.
39. G.D. Silverberg, M. Mayo, T. Saul, J. Carvalho and D. McGuire, Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers, Expert Rev Neurother 4 (2004), 97-107.
40. N. Strazielle, J.F. Ghersi-Egea, J. Ghiso, M.P. Dehouck, B. Frangione, C. Patlak, J. Fenstermacher and P. Gorevic, In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability, J Neuropathol Exp Neurol 59 (2000), 29-38.
41. L.A. Thompson, A.Y. Liauw, M.M. Ramanjulu, P. Kasireddy-Polam, S.E. Mercer, T.P. Maduskuie, M. Glicksman, A.H. Roach, J.E. Meredith, R.Q. Liu, A.P. Combs, J.N. Higaki, B. Cordell, D. Seiffert, R.C. Zaczek, D.W. Robertson and R.E. Olson, Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors, Bioorg Med Chem Lett 16 (2006), 2357-2363.
42. T. Tomita and T. Iwatsubo, gamma-secretase as a therapeutic target for treatment of Alzheimer's disease, Curr Pharm Des 12 (2006), 661-670.
43. H. Vanderstichele, E. Van Kerschaver, C. Hesse, P. Davidsson, M.A. Buyse, N. Andreasen, L. Minthon, A. Wallin, K. Blennow and E. Vanmechelen, Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma, Amyloid 7 (2000), 245-258.
44. R.A. Velliquette, T. O'Connor and R.Vassar, Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis, J Neurosci 25 (2005), 10874-10883.
45. M. Zimmermann, F. Gardoni and M. Di Luca, Molecular rationale for the pharmacological treatment of Alzheimer's disease, Drugs Aging 22(Suppl 1) (2005), 27-37.
46. B.V. Zlokovic, Clearing amyloid through the blood-brain barrier, J Neurochem 89 (2004), 807-811.